Vivex Biologics’ VIA Form+ cryopreserved viable bone allograft saw 100% radiograhpic fusion success within six months of surgery, according to a study in the Journal of Spine & Neurosurgery.
Five things to know:
1. The study followed 14 patients who had single- or two-level lumbar interbody fusion between January 2022 and March 2025, according to a Feb. 12 news release. VIA Form+ was used as a stand-alone bone graft substitute.
2. All patients had successful radiographic fusion with no implant migration subsidence, or loss of segmental lordosis throughout the follow-up period.
3. There were no adverse events associated with the allograft.
4. Patients reported significant improvements in back and leg pain, and they didn’t have any loss of neurological function observed during the study.
5. “This research underscores the transformative potential of cellular bone allografts in spinal fusion surgery,” John Burkus, MD, co-author of the study, said in the release. “The long-term results demonstrate that this innovative approach can provide consistent and reliable outcomes, even in patients with comorbidities such as smoking, diabetes and obesity.”
